Research Topics
Genomes and GenesSpecies | Ali SamiiSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Bilateral subthalamic nucleus stimulation after bilateral pallidotomies in a patient with advanced Parkinson's diseaseAli Samii
Department of Neurology, Seattle VA Puget Sound Health Care System, 1660 South Columbian Way, MS 127 S, Seattle, WA 98108, USA
Parkinsonism Relat Disord 9:159-62. 2003..The presence of cervical myelopathy and the limited response to anti-Parkinson medications in this patient underscores the importance of patient selection for functional neurosurgery in PD...- Deep brain stimulation in a patient on immunosuppressive therapy after renal transplantAli Samii
VAPSHCS, Department of Neurology, University of Washington, 1660 S Columbian Way, Mailstop 127, Seattle, WA 98108, USA
Parkinsonism Relat Disord 11:259-60. 2005..DBS surgery may be safely performed in carefully selected patients on systemic immunosuppression after renal transplant... - Telemedicine for delivery of health care in Parkinson's diseaseAli Samii
Department of Neurology and Seattle Parkinson Disease Research Education and Clinical Center Seattle PADRECC, VA Puget Sound Health Care System, Seattle, Washington 98108, USA
J Telemed Telecare 12:16-8. 2006..Our experience shows that telemedicine can be used effectively for follow-up visits with selected PD patients who are unable to travel... - Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson diseaseAli Samii
Department of Neurology, University of Washington, Seattle, Washington, USA
Mov Disord 22:1476-81. 2007..Most of the improvements in off-medication ADL scores, dyskinesia scores, complications of therapy, and medication dose reduction occurred after unilateral STN stimulation with smaller improvements after the second operation... - Spinal accessory neuropathy after deep brain stimulation for Parkinson's diseaseAli Samii
Department of Neurology, University of Washington, Seattle, WA 98108, USA
Stereotact Funct Neurosurg 85:296-8. 2007..As a result of this complication, we now map the spinal accessory nerve electrophysiologically during deep brain stimulation surgery... - Parkinson's diseaseAli Samii
Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
Lancet 363:1783-93. 2004..This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis... - Unilateral subthalamic nucleus deep brain stimulation contralateral to thalamic stimulation in Parkinson diseaseAli Samii
VAPSHCS, Department of Neurology, University of Washington School of Medicine, Mailstop 127, 1660 S Columbian Way, Seattle, WA 98108, USA
Parkinsonism Relat Disord 11:257-8. 2005..However, there was no significant improvement in activities of daily living (ADL), motor scores in the medication ON state, gait, or postural stability... - Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibodyAli Samii
Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
Mov Disord 18:1556-8. 2003..We report on details of a movement disorder that followed anti-B-cell therapy in a patient with lymphoma, and was accompanied by CRMP-5 IgG... - Statin use and the risk of Parkinson disease: a nested case control studyAli Samii
Department of Neurology, University of Washington, Seattle VA Parkinson Disease Research Education and Clinical Center PADRECC, VA Puget Sound Health Care System, 1660 S Columbian Way, MS 127, Seattle, WA 98108, USA
J Clin Neurosci 15:1272-3. 2008..94 (0.82-1.09). Our study did not show a statistically significant effect on the risk of PD with statin use... - NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studiesAli Samii
Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center, Seattle, Washington, USA
Drugs Aging 26:769-79. 2009..Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD)... - Lack of evidence for an association between UCHL1 S18Y and Parkinson's diseaseCarolyn M Hutter
Department of Epidemiology, University of Washington, Seattle, WA, USA
Eur J Neurol 15:134-9. 2008..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease... - Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's diseaseCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Ann Neurol 62:137-44. 2007..We sought to replicate these findings... - SNCA variant associated with Parkinson disease and plasma alpha-synuclein levelIgnacio F Mata
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Mailstop S 182, 1660 S Columbian Way, Seattle, WA 98108, USA
Arch Neurol 67:1350-6. 2010..A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk... - Glucocerebrosidase gene mutations: a risk factor for Lewy body disordersIgnacio F Mata
Department of Neurology, University of Washington School of Medicine, Seattle, USA
Arch Neurol 65:379-82. 2008..However, these findings have not been consistently replicated, and most studies have had substantial methodological shortcomings... - Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease riskKaren M Powers
Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
Mov Disord 23:88-95. 2008..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated... - Assessing the effects of subthalamic nucleus stimulation on gait and mobility in people with Parkinson diseaseValerie E Kelly
Department of Rehabilitation Medicine, University of Washington, Seattle, Washington 98195 6490, USA
Disabil Rehabil 32:929-36. 2010..To determine the effects of unilateral and bilateral subthalamic nucleus (STN) stimulation on gait and mobility in persons with Parkinson disease (PD)... - A novel X-linked four-repeat tauopathy with Parkinsonism and spasticityParvoneh Poorkaj
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, USA
Mov Disord 25:1409-17. 2010..In conclusion, we have identified a unique X-linked parkinsonian syndrome with variable spasticity and four-repeat tau pathology, and defined a novel candidate gene locus spanning approximately 28 Mb from Xp11.2-Xq13.3... - Gait changes in response to subthalamic nucleus stimulation in people with Parkinson disease: a case series reportValerie E Kelly
Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA
J Neurol Phys Ther 30:184-94. 2006..The purpose of this paper is to describe the effects of unilateral and bilateral STN stimulation on gait following staged stimulator implantations in a series of individuals with PD... - Mechanical failure of the electrode wire in deep brain stimulationA Alex Mohit
Department of Neurological Surgery, University of Washington School of Medicine, Seattle, WA 98108, USA
Parkinsonism Relat Disord 10:153-6. 2004..The fact that all breakages occurred near the connection wire suggests that to-and-fro motion of the DBS electrode with repeated head turning leads to fatigue and eventual disruption... - DBH -1021C-->T does not modify risk or age at onset in Parkinson's diseaseLani S Chun
Department of Neurology, University of Washington School of Medicine, Seattle, WA 98108, USA
Ann Neurol 62:99-101. 2007..Furthermore, we found no evidence for an effect of genotype on age at onset among patients. Our findings argue against DBH -1021C-->T as a risk factor or age at onset modifier in PD... - Exploring gene-environment interactions in Parkinson's diseaseColin C McCulloch
Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
Hum Genet 123:257-65. 2008..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk... - Recurrent transient global amnesia with intrathecal baclofenLucinda A Grande
Department of Anesthesiology, Box 356540, University of Washington School of Medicine, Seattle, WA 98195, USA
Anesth Analg 106:1284-7, table of contents. 2008..Baclofen-induced amnesia in rodents is a reliable model of memory impairment. In contrast, baclofen-induced memory impairment in humans is uncommon. Baclofen- associated transient global amnesia has not previously been reported... - Longitudinal diffusion tensor imaging in Huntington's DiseaseKurt E Weaver
Department of Radiology, University of Washington School of Medicine, Box 357115, Seattle, WA 98195, USA
Exp Neurol 216:525-9. 2009..These results suggest that longitudinal FA changes may serve as a neuropathological biomarker in HD... - Genetic association between alpha-synuclein and idiopathic Parkinson's diseaseDenise M Kay
New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD... - Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinicsDenise M Kay
Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
Mov Disord 21:519-23. 2006..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date... - LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia agoCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Am J Hum Genet 79:752-8. 2006..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas... - The youngest reported case of corticobasal degenerationAnna DePold Hohler
Department of Neurology, Madigan Army Medical Center, Tacoma, WA, USA
Parkinsonism Relat Disord 10:47-50. 2003..The chronic, progressive course, asymmetric limb rigidity, apraxia, focal dystonia, and lack of response to levodopa suggest CBD. To our knowledge, this is the youngest reported case of clinically probable CBD... - Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's diseaseDenise M Kay
Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
Genet Test 10:221-7. 2006..Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential... - Multisite randomized trial of deep brain stimulationKenneth Follett
Arch Neurol 62:1643-4; author reply 1644-5. 2005 - Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyAlexis Elbaz
INSERM, Unit 708, Paris, France
Lancet Neurol 5:917-23. 2006..INTERPRETATION: Our results do not lend support to the finding that the 13 SNPs reported in the original genome-wide association study are genetic susceptibility factors for Parkinson's disease... - Chronic severe dystonia after single exposure to antiemeticsMelanie Walker
Department of Neurology, University of Washington, Seattle, 98104, USA
Am J Emerg Med 24:125-7. 2006 - Holmes-like tremor of the lower extremity following brainstem hemorrhageMelanie Walker
Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
Mov Disord 22:272-4. 2007..Tremor involving the lower extremity in this setting has not been previously reported... - Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort studyMahyar Etminan
Center for Clinical Epidemiology and Evaluation, Vancouver General Hospital, Vancouver, British Columbia, Canada
J Clin Neurosci 15:576-7. 2008..A time-dependent Cox model was used to estimate adjusted rate ratios for users and non-users of NSAIDs. The results of our study did not show a protective effect of NSAIDs for PD (rate ratio 0.84, 95% CI 0.81-1.09)... - Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disordersFadi Abdi
Applied Biosystems, Framingham, MA, USA
J Alzheimers Dis 9:293-348. 2006.... - Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studiesMahyar Etminan
Department of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A1
BMJ 327:128. 2003..To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use... - Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysisMahyar Etminan
Division of Clinical Epidemiology, Royal Victoria Hospital and McGill University, Montreal, Quebec, Canada
Lancet Neurol 4:362-5. 2005..We conclude that dietary vitamin E may have a neuroprotective effect attenuating the risk of PD. These results require confirmation in randomised controlled trials... - Challenges and opportunities for pharmacoepidemiology in drug-therapy decision makingMahyar Etminan
Center for Clinical Epidemiology and Evaluation, Vancouver Hosptial, 7th Floor, 828 West 10th Avenue, Vancouver, B C, Canada
J Clin Pharmacol 46:6-9. 2006..We also discuss the potential problem of discordant results and urge pharmacoepidemiologists to develop good practice guidelines for the conduct of pharmacoepidemiologic studies... - Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysisMahyar Etminan
Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario, Canada
Drug Saf 26:439-44. 2003..Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo... - Statin therapy and risk of dementia in the elderlyMahyar Etminan
Neurology 64:1319; author reply 1319. 2005 - Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studiesMahyar Etminan
Division of Epidemiology, Royal Victoria and Vancouver Hospitals, Canada
BMJ 330:63. 2005..To explore the association between migraine and risk of ischaemic stroke... - Pharmacoepidemiology I: a review of pharmacoepidemiologic study designsMahyar Etminan
Division of Clinical Epidemiology, Royal Victoria Hospital, and McGill Health Centre, Montreal, Quebec, Canada
Pharmacotherapy 24:964-9. 2004....